Tất cả những vấn đề y học có liên quan đến cuộc sống và xã hội ... All medical issues related to life and society...
Translate
Thứ Bảy, 29 tháng 11, 2014
Understanding Gout
Understanding Gout -- Diagnosis & Treatment
How Is Gout Diagnosed?
To diagnose gout, blood and urine tests are needed but may not always give the answer.
Demonstrating high uric acid in the blood is essential, but you can have a high level of uric acid without having gout. Or you may have normal uric acid levels at the time of a gout attack.
To confirm the presence of gout, fluid drawn from the affected joint may be examined under a special polarizing microscope to see if it shows the characteristic crystals.
X-rays are useful in confirming long-term or chronic gout but often not useful in acute cases.
What Are the Treatments for Gout?
Anyone who experiences a gout attack quickly realizes that the first order of business is to ease the pain. Typically, an anti-inflammatory drug is used to control pain and inflammation. Ice applied to the affected joint is also helpful.
The immediate symptoms of gout will usually disappear in a few days or a week. Nonetheless, each instance of suspected gout should be diagnosed and treated by a doctor. Left untreated, uric acid deposits can eventually cause irreversible damage to the joints, kidneys, and other tissues.
For a gout attack, many doctors recommend oral doses of ibuprofen or naproxen, available in both prescription and nonprescription versions, or other anti-inflammatory drugs such as indomethacin. If you are taking aspirin, your doctor may recommend that you stop it temporarily. Aspirin can slow the elimination of uric acid and make gout worse. But if you take a low dose of aspirin to prevent other problems such as a heart attack, check with your doctor before stopping it.
Oral steroid medications or injections in the affected joint may be helpful in reducing pain and inflammation in severe attacks or chronic cases. However, steroids can have undesirable side effects and must always be given by a doctor.
Another treatment for acute gout is colchicine. It can reduce the risk of recurrent attacks and is most effective if taken within the first 12 hours of a gout attack. CAUTION: Colchicine may cause serious adverse side effects, especially if taken in high doses, or may interact with a number of antidepressants, tranquilizers, or antihistamines. And because of the risk of birth defects, pregnant women should not take it.
Some facts about Chocolate

Chocolate with high cacao levels has the compound phenylethylamine, the "love drug", which quickens the pulse and tricks the brain into thinking it's falling in love. A study by the Journal of Sexual Medicine found women who ate a single piece of chocolate every day enjoyed a more active sex life than those who didn't. “Go for at least 70 per cent cocoa solids or 'raw chocolate' which is also rich in powerful antioxidants,” encourages Guy.
Watermelon high in a Potentially Libido-Boosting Phytonutrients

This popular summer fruit is low in calories, but also high in potentially libido-boosting phytonutrients.
In 2008, Texas A&M research suggested that the lycopene, citrulline, and beta-carotene found in watermelon may help relax blood vessels, and provide a natural enhancement for revving up your sex drive.
Avocados good for your Heart and Arteries

The Aztecs referred to avocados as, ahem, testicles, because of their physical shape. But the scientific reason why avocados make sense as an aphrodisiac is that they are rich in unsaturated fats and low in saturated fat, making them good for your heart and your arteries. Anything that keeps the heart beating strong helps keep blood flowing to all the right places; in fact, men with underlying heart disease are twice as likely to suffer from erectile dysfunction (ED).
The Role of Ginseng in Libido

Researchers at the University of Hawaii found that women who took a ginseng supplement significantly upped their libido in a month, and 68 percent also said their overall sex life improved dramatically. "Add ginseng into your diet or try one of the many ginseng teas available," Glassman says. "Just don't jump at the sight of ginseng, though. Many energy drinks that claim to have ginseng in them also contain chemicals and tons of sugar, and there's nothing sexy about that."
Stroke Rounds: Old COX-2 Inhibitors Tied to Stroke Mortality
Published: Nov 6, 2014 | Updated: Nov 6, 2014
By John Gever, Managing Editor, MedPage Today
Reviewed by Zalman S. Agus, MD; Emeritus Professor, Perelman School of Medicine at the University of Pennsylvania and Dorothy Caputo, MA, BSN, RN, Nurse Planner
New use of nonsteroidal anti-inflammatory drugs of the first generation that selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, such as diclofenac and etodolac, was associated with increased 30-day mortality following ischemic stroke in a Danish database analysis.
Compared with patients who were not taking NSAIDs other than aspirin, those who had started on old-line COX-2 inhibitors within 60 days of admission for ischemic stroke showed a 42% increase in multivariable-adjusted risk for 30-day mortality (hazard ratio 1.42, 95% CI 1.14-1.78), according to Morten Schmidt, MD, of Aarhus University Hospital in Aarhus, Denmark, and colleagues.
No significant increase in risk was seen for other NSAIDs, including members of the newer coxib class of COX-2 inhibitors as well as nonselective agents such as naproxen, the researchers reported online inNeurology. None of the drugs examined in the study was associated with increased or decreased risk of death following hemorrhagic stroke.
"The increased mortality rate associated with COX-2 inhibition in ischemic stroke was observed only among current users, which may indicate an actual drug effect," Schmidt and colleagues noted.
Although the study offered no definitive explanation for the association, the researchers suggested several possibilities for causal mechanisms:
- Drug-induced thromboembolism leading to larger and more severe occlusions
- Increased risk of post-stroke cardiovascular events including but not limited to recurrent stroke
- Impairment in beneficial inflammatory responses to ischemic stroke
Schmidt and colleagues also observed that the popularity of older COX-2 inhibitors does not seem to have suffered from the fallout from rofecoxib's (Vioxx) market withdrawal -- even though diclofenac has previously been found to associate with increased risk of ischemic stroke events.
The current study, looking at the most severe adverse event that can occur after stroke onset, adds to the reasons to avoid such agents, the researchers contended.
"If the association is truly causal, it constitutes a strong argument for increasing the efforts to ensure that patients with a high predicted risk of arterial thromboembolism (e.g., atrial fibrillation patients with high CHA2DS2-VASc score) are not prescribed COX-2 inhibitors when alternative treatment options are available," they wrote.
On the other hand, they acknowledged that COX-2's role in the body is complicated, and inhibitors of it may help as well as harm stroke patients -- possibly both at once.
While the harm of COX-2 inhibition could come from suppression of neuroprotective factors, it is also the case that inflammatory reactions involving release of nitric oxide, interleukin-1-beta, and tumor necrosis factor -- which are believed to be neurotoxic to some degree -- are reduced by COX-2 inhibitors.
Adam Kelly, MD, of the University of Rochester Medical Center in New York state, said the study would be valuable in providing more information for prognosis in stroke patients. "We're always looking for possible predictors of mortality after stroke," said Kelly, who was not involved with the analysis.
He also noted that the authors' discussion of inflammatory processes "adds some biological plausibility" to the reported associations.
Study Details
Because the possibility that preadmission use of COX-2 inhibitors prior to stroke onset may worsen outcomes has not been studied in detail, Schmidt and colleagues decided on a relatively simple way to take a first look at the issue -- by examining registry data from Denmark, where individuals' medical histories can be accessed on a population basis.
From July 1, 2004, to Dec. 31, 2012, the researchers found just over 100,000 individuals who had experienced a first-time stroke. Of these, about half had ischemic strokes, 12% had intracerebral hemorrhages, 5% had subarachnoid hemorrhages, and for 32% the type was unspecified.
Some 11,000 of the patients were current users of prescription non-aspirin NSAIDs; 8% had records of previous use but none within 60 days of admission; and 81% showed no record of use. (Over-the-counter use may not have been captured in the data.)
Ibuprofen was the most commonly prescribed agent (51% of current users), followed by diclofenac (27%), etodolac (11%), naproxen (3%), and celecoxib (1%). Records indicated that 15.5% of ischemic stroke patients were using NSAIDs after discharge, with smaller proportions of hemorrhagic stroke patients showing postdischarge use.
Death within 30 days of admission was recorded for 8.7% of the ischemic stroke patients, 35% of those with intracerebral hemorrhage, 24.5% of the subarachnoid hemorrhage group, and 14.3% of those with unspecified types.
Any NSAID use started 60 days or less before admission for ischemic stroke was associated with increased risk of 30-day death with a nonsignificant hazard ratio of 1.18 (95% CI 0.95-1.47) versus nonusers, after adjustment for propensity scores and a host of other potential confounders. The risk associated with new use of any COX-2 inhibitor (both old-line and coxib) was nearly the same at 1.21.
Schmidt and colleagues found a hint that the coxib class may also increase the risk of 30-day mortality following ischemic stroke -- a propensity- and multivariable-adjusted hazard ratio of 1.41 versus nonusers -- but there were so few patients taking these agents that the result did not achieve statistical significance (95% CI 0.37-5.31).
In contract, there was not even the faintest suggestion that NSAIDs of any type worsened outcomes after hemorrhagic strokes. New use of nonselective NSAIDs in people later diagnosed with subarachnoid hemorrhage, in fact, was associated with reduced mortality after adjustments (HR 0.58, 95% CI 0.37-0.91).
Kelly told MedPage Today that the findings, in and of themselves, would not justify withholding older COX-2 inhibitors from all patients. He suggested that these medications may be the best choices "from a quality-of-life standpoint" for some patients with musculoskeletal conditions. "It's a really important patient-centered question that the patient and the provider need to address," he said.
Đăng ký:
Bài đăng (Atom)